Collectively, these data suggest that miR-200b suppresses the integrin β1-AKT pathway via targeting Kindlin-2, which may mediate the role of miR-200b in mitigating ESCC cell invasiveness. Here, FERMT2 is linked to esophageal squamous cell carcinoma.